melanotan cycle Ii - Ac-nle-cycle[asp-his-d-phe-arg-trp-lys]-nh2, 1024.2 Molecular Weight - Enhance Sexual Desire, Induce Skin Tanning, Minimal Side Effects at Best Price in Florida City MT1 (Melanotan 1) Dosing: Clinical

Species 0.000 description 5 210000000601 blood cell Anatomy 0.000 description 5 150000002019 disulfides Chemical class 0.000 description 5 229940079593 drug Drugs 0.000 description 5 230000000694 effects Effects 0.000 description 5 210000003743 erythrocyte Anatomy 0.000 description 5 210000003470 mitochondria Anatomy 0.000 description 5 230000001590 oxidative effect Effects 0.000 description 5 230000009467 reduction Effects 0.000 description 5 ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4 ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4 RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4 206010016654 Fibrosis Diseases 0.000 description 4 102000005720 Glutathione transferase Human genes 0.000 description 4 108010070675 Glutathione transferase Proteins 0.000 description 4 DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4 XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4 230000003915 cell function Effects 0.000 description 4 230000007882 cirrhosis Effects 0.000 description 4 208000019425 cirrhosis of liver Diseases 0.000 description 4 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4 208000006454 hepatitis Diseases 0.000 description 4 231100000283 hepatitis Toxicity 0.000 description 4 239000003978 infusion fluid Substances 0.000 description 4 230000003859 lipid peroxidation Effects 0.000 description 4 201000001441 melanoma Diseases 0.000 description 4 238000000034 method Methods 0.000 description 4 238000010606 normalization Methods 0.000 description 4 230000005855 radiation Effects 0.000 description 4 230000035806 respiratory chain Effects 0.000 description 4 150000003573 thiols Chemical class 0.000 description 4 LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3 WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3 206010027476 Metastases Diseases 0.000 description 3 241000283973 Oryctolagus cuniculus Species 0.000 description 3 230000000172 allergic effect Effects 0.000 description 3 230000003281 allosteric effect Effects 0.000 description 3 208000010668 atopic eczema Diseases 0.000 description 3 230000015556 catabolic process Effects 0.000 description 3 210000000170 cell membrane Anatomy 0.000 description 3 KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3 238000006731 degradation reaction Methods 0.000 description 3 230000018044 dehydration Effects 0.000 description 3 238000006297 dehydration reaction Methods 0.000 description 3 230000004069 differentiation Effects 0.000 description 3 238000006911 enzymatic reaction Methods 0.000 description 3 235000013922 glutamic acid Nutrition 0.000 description 3 239000004220 glutamic acid Substances 0.000 description 3 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3 238000011534 incubation Methods 0.000 description 3 230000002757 inflammatory effect Effects 0.000 description 3 238000001990 intravenous administration Methods 0.000 description 3 208000019423 liver disease Diseases 0.000 description 3 230000003211 malignant effect Effects 0.000 description 3 230000007246 mechanism Effects 0.000 description 3 210000003463 organelle Anatomy 0.000 description 3 230000036542 oxidative stress Effects 0.000 description 3 210000002966 serum Anatomy 0.000 description 3 238000007920 subcutaneous administration Methods 0.000 description 3 238000006467 substitution reaction Methods 0.000 description 3 231100000331 toxic Toxicity 0.000 description 3 230000002588 toxic effect Effects 0.000 description 3 GVJHHUAWPYXKBD-UHFFFAOYSA-N ()--Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2 OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2 208000031229 Cardiomyopathies Diseases 0.000 description 2 102000018832 Cytochromes Human genes 0.000 description 2 108010052832 Cytochromes Proteins 0.000 description 2 BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2 MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2 208000004930 Fatty Liver Diseases 0.000 description 2 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 2 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 2 108010036164 Glutathione synthase Proteins 0.000 description 2 102100034294 Glutathione synthetase Human genes 0.000 description 2 239000004471 Glycine Substances 0.000 description 2 102000001554 Hemoglobins Human genes 0.000 description 2 108010054147 Hemoglobins Proteins 0.000 description 2 206010019708 Hepatic steatosis Diseases 0.000 description 2 238000012404 In vitro experiment Methods 0.000 description 2 RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 2 WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2 241000124008 Mammalia Species 0.000 description 2 206010028813 Nausea Diseases 0.000 description 2 208000012902 Nervous system disease Diseases 0.000 description 2 208000025966 Neurological disease Diseases 0.000 description 2 102000004316 Oxidoreductases Human genes 0.000 description 2 108090000854 Oxidoreductases Proteins 0.000 description 2 206010063493 Premature ageing Diseases 0.000 description 2 208000032038 Premature aging Diseases 0.000 description 2 BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2 230000009471 action Effects 0.000 description 2 230000001154 acute effect Effects 0.000 description 2 239000002671 adjuvant Substances 0.000 description 2 230000033228 biological regulation Effects 0.000 description 2 230000005540 biological transmission Effects 0.000 description 2 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2 230000005779 cell damage Effects 0.000 description 2 230000030833 cell death Effects 0.000 description 2 230000001684 chronic effect Effects 0.000 description 2 XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2 235000018417 cysteine Nutrition 0.000 description 2 230000007123 defense Effects 0.000 description 2 230000007850 degeneration Effects 0.000 description 2 230000003412 degenerative effect Effects 0.000 description 2 230000001419 dependent effect Effects 0.000 description 2 238000001784 detoxification Methods 0.000 description 2 235000014113 dietary fatty acids Nutrition 0.000 description 2 238000009792 diffusion process Methods 0.000 description 2 230000027721 electron transport chain Effects 0.000 description 2 230000003511 endothelial effect Effects 0.000 description 2 229930195729 fatty acid Natural products 0.000 description 2 239000000194 fatty acid Substances 0.000 description 2 150000004665 fatty acids Chemical class 0.000 description 2 208000010706 fatty liver disease Diseases 0.000 description 2 239000011521 glass Substances 0.000 description 2 210000002443 helper t lymphocyte Anatomy 0.000 description 2 230000001900 immune effect Effects 0.000 description 2 230000006872 improvement Effects 0.000 description 2 238000000338 in vitro Methods 0.000 description 2 230000005764 inhibitory process Effects 0.000 description 2 238000002347 injection Methods 0.000 description 2 239000007924 injection Substances 0.000 description 2 230000035987 intoxication Effects 0.000 description 2 231100000566 intoxication Toxicity 0.000 description 2 238000001361 intraarterial administration Methods 0.000 description 2 238000007918 intramuscular administration Methods 0.000 description 2 238000010253 intravenous injection Methods 0.000 description 2 210000004185 liver Anatomy 0.000 description 2 210000002540 macrophage Anatomy 0.000 description 2 229940126601 medicinal product Drugs 0.000 description 2 230000002503 metabolic effect Effects 0.000 description 2 150000002772 monosaccharides Chemical class 0.000 description 2 210000004400 mucous membrane Anatomy 0.000 description 2 208000010125 myocardial infarction Diseases 0.000 description 2 210000000822 natural killer cell Anatomy 0.000 description 2 230000008693 nausea Effects 0.000 description 2 238000011275 oncology therapy Methods 0.000 description 2 238000005457 optimization Methods 0.000 description 2 150000001451 organic peroxides Chemical class 0.000 description 2 YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2 150000002926 oxygen Chemical class 0.000 description 2 230000036961 partial effect Effects 0.000 description 2 239000002504 physiological saline solution Substances 0.000 description 2 230000002265 prevention Effects 0.000 description 2 230000008569 process Effects 0.000 description 2 230000035755 proliferation Effects 0.000 description 2 230000001681 protective effect Effects 0.000 description 2 210000003456 pulmonary alveoli Anatomy 0.000 description 2 239000002516 radical scavenger Substances 0.000 description 2 238000006479 redox reaction Methods 0.000 description 2 229910052711 selenium Inorganic materials 0.000 description 2 239000011669 selenium Substances 0.000 description 2 231100000240 steatosis hepatitis Toxicity 0.000 description 2 230000034005 thiol-disulfide exchange Effects 0.000 description 2 230000000451 tissue damage Effects 0.000 description 2 239000003440 toxic substance Substances 0.000 description 2 239000011573 trace mineral Substances 0.000 description 2 235000013619 trace mineral Nutrition 0.000 description 2 238000012546 transfer Methods 0.000 description 2 238000002054 transplantation Methods 0.000 description 2 230000004102 tricarboxylic acid cycle Effects 0.000 description 2 230000003313 weakening effect Effects 0.000 description 2 FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1 208000030090 Acute Disease Diseases 0.000 description 1 206010002091 Anaesthesia Diseases 0.000 description 1 208000000058 Anaplasia Diseases 0.000 description 1 206010002383 Angina Pectoris Diseases 0.000 description 1 206010003210 Arteriosclerosis Diseases 0.000 description 1 206010003694 Atrophy Diseases 0.000 description 1 102000016938 Catalase Human genes 0.000 description 1 108010053835 Catalase Proteins 0.000 description 1 208000002177 Cataract Diseases 0.000 description 1 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1 208000017667 Chronic Disease Diseases 0.000 description 1 206010010356 Congenital anomaly Diseases 0.000 description 1 208000028006 Corneal injury Diseases 0.000 description 1 101710088194 Dehydrogenase Proteins 0.000 description 1 108091006149 Electron carriers Proteins 0.000 description 1 239000004593 Epoxy Substances 0.000 description 1 102000003983 Flavoproteins Human genes 0.000 description 1 108010057573 Flavoproteins Proteins 0.000 description 1 208000001034 Frostbite Diseases 0.000 description 1 RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1 206010017711 Gangrene Diseases 0.000 description 1 WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1 HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1 206010020751 Hypersensitivity Diseases 0.000 description 1 206010020880 Hypertrophy Diseases 0.000 description 1 206010021143 Hypoxia Diseases 0.000 description 1 FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1 239000004201 L-cysteine Substances 0.000 description 1 235000013878 L-cysteine Nutrition 0.000 description 1 FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1 229930195722 L-methionine Natural products 0.000 description 1 206010067125 Liver injury Diseases 0.000 description 1 206010025327 Lymphopenia Diseases 0.000 description 1 FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1 CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1 102000035195 Peptidases Human genes 0.000 description 1 108091005804 Peptidases Proteins 0.000 description 1 ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1 241000700157 Rattus norvegicus Species 0.000 description 1 241000606701 Rickettsia Species 0.000 description 1 XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1 FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1 101710172711 Structural protein Proteins 0.000 description 1 210000001744 T-lymphocyte Anatomy 0.000 description 1 102000004357 Transferases Human genes 0.000 description 1 108090000992 Transferases Proteins 0.000 description 1 208000025865 Ulcer Diseases 0.000 description 1 241000700605 Viruses Species 0.000 description 1 FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1 229930003427 Vitamin E Natural products 0.000 description 1 206010052428 Wound Diseases 0.000 description 1 208000027418 Wounds and injury Diseases 0.000 description 1 HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1 239000002253 acid Substances 0.000 description 1 239000013543 active substance Substances 0.000 description 1 238000009098 adjuvant therapy Methods 0.000 description 1 230000032683 aging Effects 0.000 description 1 230000002152 alkylating effect Effects 0.000 description 1 OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1 FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1 208000026935 allergic disease Diseases 0.000 description 1 230000007815 allergy Effects 0.000 description 1 230000008850 allosteric inhibition Effects 0.000 description 1 210000001132 alveolar macrophage Anatomy 0.000 description 1 239000003708 ampul Substances 0.000 description 1 230000037005 anaesthesia Effects 0.000 description 1 208000007502 anemia Diseases 0.000 description 1 239000002246 antineoplastic agent Substances 0.000 description 1 238000013459 approach Methods 0.000 description 1 208000011775 arteriosclerosis disease Diseases 0.000 description 1 230000037444 atrophy Effects 0.000 description 1 210000003719 b-lymphocyte Anatomy 0.000 description 1 230000001580 bacterial effect Effects 0.000 description 1 230000004888 barrier function Effects 0.000 description 1 230000008901 benefit Effects 0.000 description 1 TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1 235000013734 beta-carotene Nutrition 0.000 description 1 239000011648 beta-carotene Substances 0.000 description 1 229960002747 betacarotene Drugs 0.000 description 1 210000004556 brain Anatomy 0.000 description 1 239000002775 capsule Substances 0.000 description 1 229940077731 carbohydrate nutrients Drugs 0.000 description 1 150000001720 carbohydrates Chemical class 0.000 description 1 235000014633 carbohydrates Nutrition 0.000 description 1 229910052799 carbon Inorganic materials 0.000 description 1 125000004432 carbon atom Chemical group C* 0.000 description 1 239000000969 carrier Substances 0.000 description 1 230000006652 catabolic pathway Effects 0.000 description 1 230000003197 catalytic effect Effects 0.000 description 1 230000010261 cell growth Effects 0.000 description 1 208000037887 cell injury Diseases 0.000 description 1 230000009920 chelation Effects 0.000 description 1 239000003795 chemical substances by application Substances 0.000 description 1 238000002512 chemotherapy Methods 0.000 description 1 230000015271 coagulation Effects 0.000 description 1 238000005345 coagulation Methods 0.000 description 1 239000005515 coenzyme Substances 0.000 description 1 230000006957 competitive inhibition Effects 0.000 description 1 230000000295 complement effect Effects 0.000 description 1 208000029078 coronary artery disease Diseases 0.000 description 1 239000000824 cytostatic agent Substances 0.000 description 1 230000001085 cytostatic effect Effects 0.000 description 1 229940127089 cytotoxic agent Drugs 0.000 description 1 238000006114 decarboxylation reaction Methods 0.000 description 1 238000000354 decomposition reaction Methods 0.000 description 1 230000007812 deficiency Effects 0.000 description 1 238000006356 dehydrogenation reaction Methods 0.000 description 1 238000004925 denaturation Methods 0.000 description 1 230000036425 denaturation Effects 0.000 description 1 230000001066 destructive effect Effects 0.000 description 1 231100000673 doseresponse relationship Toxicity 0.000 description 1 239000006196 drop Substances 0.000 description 1 230000004064 dysfunction Effects 0.000 description 1 239000003792 electrolyte Substances 0.000 description 1 210000003617 erythrocyte membrane Anatomy 0.000 description 1 239000000945 filler Substances 0.000 description 1 229960002737 fructose Drugs 0.000 description 1 125000000524 functional group Chemical group 0.000 description 1 WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1 239000007789 gas Substances 0.000 description 1 238000002695 general anesthesia Methods 0.000 description 1 229910052732 germanium Inorganic materials 0.000 description 1 GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1 239000008103 glucose Substances 0.000 description 1 239000008187 granular material Substances 0.000 description 1 210000003714 granulocyte Anatomy 0.000 description 1 230000012010 growth Effects 0.000 description 1 230000035876 healing Effects 0.000 description 1 229910001385 heavy metal Inorganic materials 0.000 description 1 229960002897 heparin Drugs 0.000 description 1 229920000669 heparin Polymers 0.000 description 1 231100000234 hepatic damage Toxicity 0.000 description 1 210000005260 human cell Anatomy 0.000 description 1 150000002431 hydrogen Chemical class 0.000 description 1 150000002432 hydroperoxides Chemical class 0.000 description 1 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1 238000001727 in vivo Methods 0.000 description 1 208000015181 infectious disease Diseases 0.000 description 1 208000021267 infertility disease Diseases 0.000 description 1 238000011081 inoculation Methods 0.000 description 1 210000003093 intracellular space Anatomy 0.000 description 1 238000007912 intraperitoneal administration Methods 0.000 description 1 230000002601 intratumoral effect Effects 0.000 description 1 238000009533 lab test Methods 0.000 description 1 201000002364 leukopenia Diseases 0.000 description 1 231100001022 leukopenia Toxicity 0.000 description 1 239000007788 liquid Substances 0.000 description 1 230000008818 liver damage Effects 0.000 description 1 230000005976 liver dysfunction Effects 0.000 description 1 238000011866 long-term treatment Methods 0.000 description 1 231100001023 lymphopenia Toxicity 0.000 description 1 229910052749 magnesium Inorganic materials 0.000 description 1 239000011777 magnesium Substances 0.000 description 1 238000012423 maintenance Methods 0.000 description 1 238000002483 medication Methods 0.000 description 1 239000000155 melt Substances 0.000 description 1 230000003340 mental effect Effects 0.000 description 1 208000030159 metabolic disease Diseases 0.000 description 1 230000037353 metabolic pathway Effects 0.000 description 1 239000002207 metabolite Substances 0.000 description 1 229910021645 metal ion Inorganic materials 0.000 description 1 230000009401 metastasis Effects 0.000 description 1 229960004452 methionine Drugs 0.000 description 1 210000001700 mitochondrial membrane Anatomy 0.000 description 1 230000000394 mitotic effect Effects 0.000 description 1 239000000203 mixture Substances 0.000 description 1 210000001616 monocyte Anatomy 0.000 description 1 210000004877 mucosa Anatomy 0.000 description 1 150000002831 nitrogen free-radicals Chemical class 0.000 description 1 231100000252 nontoxic Toxicity 0.000 description 1 230000003000 nontoxic effect Effects 0.000 description 1 230000001473 noxious effect Effects 0.000 description 1 239000002773 nucleotide Substances 0.000 description 1 125000003729 nucleotide group Chemical group 0.000 description 1 239000002674 ointment Substances 0.000 description 1 239000006186 oral dosage form Substances 0.000 description 1 210000000056 organ Anatomy 0.000 description 1 230000008816 organ damage Effects 0.000 description 1 KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1 238000002640 oxygen therapy Methods 0.000 description 1 230000001575 pathological effect Effects 0.000 description 1 230000001991 pathophysiological effect Effects 0.000 description 1 230000035699 permeability Effects 0.000 description 1 230000002085 persistent effect Effects 0.000 description 1 210000004180 plasmocyte Anatomy 0.000 description 1 230000008092 positive effect Effects 0.000 description 1 229910052700 potassium Inorganic materials 0.000 description 1 239000011591 potassium Substances 0.000 description 1 239000000843 powder Substances 0.000 description 1 239000002243 precursor Substances 0.000 description 1 238000004321 preservation Methods 0.000 description 1 235000019833 protease Nutrition 0.000 description 1 230000002685 pulmonary effect Effects 0.000 description 1 230000009325 pulmonary function Effects 0.000 description 1 238000007348 radical reaction Methods 0.000 description 1 238000001959 radiotherapy Methods 0.000 description 1 230000036647 reaction Effects 0.000 description 1 230000000306 recurrent effect Effects 0.000 description 1 230000008929 regeneration Effects 0.000 description 1 238000011069 regeneration method Methods 0.000 description 1 230000001373 regressive effect Effects 0.000 description 1 108091006091 regulatory enzymes Proteins 0.000 description 1 230000000241 respiratory effect Effects 0.000 description 1 230000029058 respiratory gaseous exchange Effects 0.000 description 1 210000002345 respiratory system Anatomy 0.000 description 1 210000001525 retina Anatomy 0.000 description 1 238000012216 screening Methods 0.000 description 1 108010049797 selenium-independent glutathione peroxidase Proteins 0.000 description 1 229910052710 silicon Inorganic materials 0.000 description 1 239000010703 silicon Substances 0.000 description 1 208000013363 skeletal muscle disease Diseases 0.000 description 1 239000007921 spray Substances 0.000 description 1 238000009102 step therapy Methods 0.000 description 1 238000003860 storage Methods 0.000 description 1 238000005728 strengthening Methods 0.000 description 1 239000000758 substrate Substances 0.000 description 1 239000000829 suppository Substances 0.000 description 1 239000004094 surface-active agent Substances 0.000 description 1 238000003786 synthesis reaction Methods 0.000 description 1 230000009897 systematic effect Effects 0.000 description 1 239000003826 tablet Substances 0.000 description 1 229940124597 therapeutic agent Drugs 0.000 description 1 206010043554 thrombocytopenia Diseases 0.000 description 1 231100000827 tissue damage Toxicity 0.000 description 1 230000007704 transition Effects 0.000 description 1 210000004881 tumor cell Anatomy 0.000 description 1 230000004614 tumor growth Effects 0.000 description 1 231100000397 ulcer Toxicity 0.000 description 1 238000002255 vaccination Methods 0.000 description 1 210000003462 vein Anatomy 0.000 description 1 235000019155 vitamin A Nutrition 0.000 description 1 239000011719 vitamin A Substances 0.000 description 1 235000019165 vitamin E Nutrition 0.000 description 1 229940046009 vitamin E Drugs 0.000 description 1 239000011709 vitamin E Substances 0.000 description 1 229940045997 vitamin a Drugs 0.000 description 1 239000002676 xenobiotic agent Substances 0.000 description 1 239000011701 zinc Substances 0.000 description 1 229910052725 zinc Inorganic materials 0.000 description 1 OENHQHLEOONYIE-JLTXGRSLSA-N -Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1 Classifications AHUMAN NECESSITIES A61MEDICAL OR VETERINARY SCIENCE

& Tanner, J

However, more research is needed to support these claims

Patients respond well to: Knee surgery corrects the anatomical issues responsible for knee pain

Eur J Clin Invest 50(4):e13211